BACKGROUND/AIMS: We measured aspartyl (asparaginyl)-beta-hydroxylase (AAH) gene expression in human hepatocelluar carcinoma and surrounding uninvolved liver at both the mRNA and protein level and examined the regulation and function of this enzyme. METHODS: Since growth of HCC is mediated by signaling through the insulin-receptor substrate, type 1 (IRS-1), we examined-if AAH is a downstream gene regulated by insulin and IGF-1 in HCC cells. In addition, IRS-1 regulation of AAH was examined in a transgenic (Tg) mouse model in which the human (h) IRS-1 gene was over-expressed in the liver, and an in vitro model in which a C-terminus truncated dominant-negative hIRS-1 cDNA (hIRS-DeltaC) was over-expressed in FOCUS HCC cells. The direct effects of AAH on motility and invasiveness were examined in AAH-transfected HepG2 cells. RESULTS: Insulin and IGF-1 stimulation increased AAH mRNA and protein expression and motility in FOCUS and Hep-G2 cells. These effects were mediated by signaling through the Erk MAPK and PI3 kinase-Akt pathways. Over-expression of hIRS-1 resulted in high levels of AAH in Tg mouse livers, while over-expression of hIRS-DeltaC reduced AAH expression, motility, and invasiveness in FOCUS cells. Finally, over-expression of AAH significantly increased motility and invasiveness in HepG2 cells, whereas siRNA inhibition of AAH expression significantly reduced directional motility in FOCUS cells. CONCLUSIONS: The results suggest that enhanced AAH gene activity is a common feature of human HCC and growth factor signaling through IRS-1 regulates AAH expression and increases motility and invasion of HCC cells. Therefore, AAH may represent an important target for regulating tumor growth in vivo.
BACKGROUND/AIMS: We measured aspartyl (asparaginyl)-beta-hydroxylase (AAH) gene expression in humanhepatocelluar carcinoma and surrounding uninvolved liver at both the mRNA and protein level and examined the regulation and function of this enzyme. METHODS: Since growth of HCC is mediated by signaling through the insulin-receptor substrate, type 1 (IRS-1), we examined-if AAH is a downstream gene regulated by insulin and IGF-1 in HCC cells. In addition, IRS-1 regulation of AAH was examined in a transgenic (Tg) mouse model in which the human (h) IRS-1 gene was over-expressed in the liver, and an in vitro model in which a C-terminus truncated dominant-negative hIRS-1 cDNA (hIRS-DeltaC) was over-expressed in FOCUS HCC cells. The direct effects of AAH on motility and invasiveness were examined in AAH-transfected HepG2 cells. RESULTS:Insulin and IGF-1 stimulation increased AAH mRNA and protein expression and motility in FOCUS and Hep-G2 cells. These effects were mediated by signaling through the ErkMAPK and PI3 kinase-Akt pathways. Over-expression of hIRS-1 resulted in high levels of AAH in Tg mouse livers, while over-expression of hIRS-DeltaC reduced AAH expression, motility, and invasiveness in FOCUS cells. Finally, over-expression of AAH significantly increased motility and invasiveness in HepG2 cells, whereas siRNA inhibition of AAH expression significantly reduced directional motility in FOCUS cells. CONCLUSIONS: The results suggest that enhanced AAH gene activity is a common feature of human HCC and growth factor signaling through IRS-1 regulates AAH expression and increases motility and invasion of HCC cells. Therefore, AAH may represent an important target for regulating tumor growth in vivo.
Authors: Suzanne M de la Monte; Maoyin Pang; Rajeev Chaudhry; Kevin Duan; Lisa Longato; Jade Carter; Jiyun Ouh; Jack R Wands Journal: Hepatol Res Date: 2011-02-24 Impact factor: 4.288
Authors: Diana Lizarazo; Valerie Zabala; Ming Tong; Lisa Longato; Suzanne M de la Monte Journal: J Gastroenterol Hepatol Date: 2013-10 Impact factor: 4.029
Authors: Yoshito Tomimaru; Hironori Koga; Hirohisa Yano; Suzanne de la Monte; Jack R Wands; Miran Kim Journal: Liver Int Date: 2013-05-08 Impact factor: 5.828
Authors: Masafumi Shimoda; Yoshito Tomimaru; Kevin P Charpentier; Howard Safran; Rolf I Carlson; Jack Wands Journal: J Hepatol Date: 2012-01-13 Impact factor: 25.083
Authors: Yoshito Tomimaru; Sasmita Mishra; Howard Safran; Kevin P Charpentier; William Martin; Anne S De Groot; Stephen H Gregory; Jack R Wands Journal: Vaccine Date: 2015-01-25 Impact factor: 3.641
Authors: Elizabeth Silbermann; Peter Moskal; Nathaniel Bowling; Ming Tong; Suzanne M de la Monte Journal: Behav Brain Funct Date: 2010-11-04 Impact factor: 3.759
Authors: Nathan Salomonis; Brandon Nelson; Karen Vranizan; Alexander R Pico; Kristina Hanspers; Allan Kuchinsky; Linda Ta; Mark Mercola; Bruce R Conklin Journal: PLoS Comput Biol Date: 2009-11-06 Impact factor: 4.475
Authors: C A Barton; B S Gloss; W Qu; A L Statham; N F Hacker; R L Sutherland; S J Clark; P M O'Brien Journal: Br J Cancer Date: 2009-11-24 Impact factor: 7.640